Universal Beteiligungs und Servicegesellschaft mbH Sells 28,088 Shares of Glaukos Corporation $GKOS

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Glaukos Corporation (NYSE:GKOS) by 47.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,175 shares of the medical instruments supplier’s stock after selling 28,088 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.05% of Glaukos worth $2,542,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AlphaQuest LLC increased its position in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 136 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Glaukos by 909.7% during the second quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock worth $129,000 after buying an additional 1,128 shares in the last quarter. M&T Bank Corp bought a new position in shares of Glaukos in the second quarter valued at approximately $203,000. Finally, Inspire Advisors LLC acquired a new position in shares of Glaukos in the 2nd quarter worth approximately $208,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: FDA approves re-administration of iDose TR — Approval increases the product’s commercial flexibility and addressable market (potential for repeat treatments and improved lifetime value per patient), which was the primary catalyst for the intraday rally. Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
• Positive Sentiment: Analyst price-target increase from BTIG — BTIG raised its target to $131 and keeps a Buy rating, implying roughly double-digit upside from current levels and signaling continued analyst confidence in growth from interventional glaucoma products. GKOS price target raised by BTIG
• Positive Sentiment: Zacks reiterates hold/retain thesis highlighting iDose and iStent synergy and scale benefits — Zacks notes growing adoption of interventional glaucoma and operating-leverage potential, suggesting upside as revenue scales despite near-term margin pressure. Here’s Why You Should Retain Glaukos Stock in Your Portfolio Now
• Neutral Sentiment: Consensus rating sits at “Moderate Buy” — The analyst consensus supports modest upside but stops short of unanimous conviction; useful context but not a fresh catalyst on its own. Glaukos Given Consensus Rating of “Moderate Buy” by Analysts
• Negative Sentiment: Recent insider sales — Two named insiders sold shares (Joseph Gilliam ~10,498 shares; Marc Stapley ~15,000 shares). Insider selling can be interpreted as a near-term negative signal for sentiment, even if sales may be for personal/liquidity reasons. Joseph Gilliam Sells 10,498 Shares Marc Stapley Sells 15,000 Shares

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of recent analyst reports. Stifel Nicolaus raised their price target on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Citigroup raised their target price on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Piper Sandler reiterated an “overweight” rating and set a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. Finally, Truist Financial boosted their target price on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average price target of $132.54.

Insider Activity

In related news, CFO Alex R. Thurman sold 315 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total value of $33,075.00. Following the sale, the chief financial officer directly owned 50,488 shares in the company, valued at $5,301,240. This trade represents a 0.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Joseph E. Gilliam sold 19,340 shares of Glaukos stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the transaction, the chief operating officer directly owned 92,366 shares in the company, valued at $8,312,940. The trade was a 17.31% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 329,655 shares of company stock valued at $37,752,234. Insiders own 5.80% of the company’s stock.

Glaukos Stock Down 4.1%

Shares of NYSE GKOS opened at $118.84 on Friday. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $161.78. The firm’s 50-day moving average is $112.81 and its 200-day moving average is $96.75. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $6.83 billion, a PE ratio of -77.17 and a beta of 0.67.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. During the same period in the previous year, the firm posted ($0.28) earnings per share. Glaukos’s revenue for the quarter was up 38.1% compared to the same quarter last year. Equities analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.